Lupin, Avas unveil myotonia treatment NaMuscla in Italy Ruchika Sharma29 Jan 2025 11:30 AM ISTMumbai: Global pharma major Lupin Limited and Avas Pharmaceuticals SRL have announced the launch of Lupin's orphan drug NaMuscla (mexiletine) in...
Lupin arm ink pact with Celnova for distribution of Orphan Drug NaMuscla in Argentina, Colombia Ruchika Sharma28 Sept 2024 11:10 AM ISTMumbai: Global pharma major, Lupin Limited has announced that its subsidiary Lupin Atlantis Holdings SA has entered into a distribution agreement...
Spain approves reimbursement of Lupin NaMuscla for symptomatic treatment of myotonia in adults with non-dystrophic myotonic disorders Ruchika Sharma10 Jan 2023 11:35 AM ISTNDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain, and is...
Lupin, Medis ink pact for Orphan Drug NaMuscla Ruchika Sharma10 Feb 2022 12:16 PM ISTNaMuscla reduces myotonia symptoms in the people with NDM, resulting in a significant improvement in quality of life and other functional and...
Lupin signs agreement with Macure Pharma, others to commercialise NaMuscla in Europe Ruchika Sharma4 Jun 2020 12:28 PM ISTLupin will continue the commercialization of NaMuscla® in Germany and the UK and will launch the product in Austria and France later this year
